Abbott receives fda approval for navitor™, a next-generation tavi system designed to treat aortic stenosis

Abbott's new navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant  transcatheter aortic valve implantation (tavi) offers minimally invasive alternative to surgery for people with aortic stenosis, a common and life-threatening heart valve disease    abbott park, ill., jan. 17, 2023 /prnewswire/ -- abbott (nyse: abt) today announced that the u.s. food and drug administration (fda) has approved the company's latest-generation transcatheter aortic valve implantation (tavi) system, navitor™, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery.
ABT Ratings Summary
ABT Quant Ranking